Deniz Kirik

List of Publications by Year
in descending order

132 papers	14,336 citations	19657 61 h-index	19749 117 g-index
136 all docs	136 docs citations	136 times ranked	12531 citing authors

#	Article	IF	Citations
1	Neuronal replacement from endogenous precursors in the adult brain after stroke. Nature Medicine, 2002, 8, 963-970.	30.7	2,613
2	Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of Î±-Synuclein in the Nigrostriatal System. Journal of Neuroscience, 2002, 22, 2780-2791.	3.6	633
3	Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain, 2007, 130, 1819-1833.	7.6	569
4	Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System. Journal of Neuroscience, 2000, 20, 4686-4700.	3.6	386
5	Nigrostriatal Â-synucleinopathy induced by viral vector-mediated overexpression of human Â-synuclein: A new primate model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2884-2889.	7.1	382
6	l-DOPA-Induced Dyskinesia in the Intrastriatal 6-Hydroxydopamine Model of Parkinson's Disease: Relation to Motor and Cellular Parameters of Nigrostriatal Function. Neurobiology of Disease, 2002, 10, 165-186.	4.4	378
7	A General Chemical Method to Regulate Protein Stability in the Mammalian Central Nervous System. Chemistry and Biology, 2010, 17, 981-988.	6.0	313
8	Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons. Journal of Neuroscience, 1998, 18, 4929-4937.	3.6	308
9	Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nature Neuroscience, 2004, 7, 105-110.	14.8	262
10	Cell transplantation in Parkinson's disease: how can we make it work?. Trends in Neurosciences, 2005, 28, 86-92.	8.6	249
11	Studies on Neuroprotective and Regenerative Effects of GDNF in a Partial Lesion Model of Parkinson's Disease. Neurobiology of Disease, 1997, 4, 186-200.	4.4	239
12	Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinsonâ€™s disease. Brain, 2014, 137, 2493-2508.	7.6	232
13	Î±-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Human Molecular Genetics, 2012, 21, 3173-3192.	2.9	228
14	Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain, 2008, 131, 3380-3394.	7.6	223
15	Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. European Journal of Neuroscience, 1999, 11, 1554-1566.	2.6	219
16	Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease. Journal of Neuroscience, 2005, 25, 769-777.	3.6	212
17	Identification of Dopaminergic Neurons of Nigral and Ventral Tegmental Area Subtypes in Grafts of Fetal Ventral Mesencephalon Based on Cell Morphology, Protein Expression, and Efferent Projections. Journal of Neuroscience, 2005, 25, 6467-6477.	3.6	212
18	Microglia Acquire Distinct Activation Profiles Depending on the Degree of Î±-Synuclein Neuropathology in a rAAV Based Model of Parkinson's Disease. PLoS ONE, 2010, 5, e8784.	2.5	207

#	Article	IF	Citations
19	Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain, 2007, 130, 799-815.	7.6	186
20	Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. European Journal of Neuroscience, 2000, 12, 3871-3882.	2.6	182
21	Serotonin Neuron Transplants Exacerbate l-DOPA- Induced Dyskinesias in a Rat Model of Parkinson's Disease. Journal of Neuroscience, 2007, 27, 8011-8022.	3.6	180
22	Boosting chaperone-mediated autophagy in vivo mitigates Î±-synuclein-induced neurodegeneration. Brain, 2013, 136, 2130-2146.	7.6	175
23	Murine models of acute neuronopathic Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17483-17488.	7.1	160
24	GDNF fails to exert neuroprotection in a rat Â-synuclein model of Parkinson's disease. Brain, 2011, 134, 2302-2311.	7.6	157
25	Animal models of Parkinson's disease: Limits and relevance to neuroprotection studies. Movement Disorders, 2013, 28, 61-70.	3.9	156
26	Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion. Nature Cell Biology, 2008, 10, 584-592.	10.3	143
27	Overexpression of Glial Cell Line-Derived Neurotrophic Factor Using a Lentiviral Vector Induces Time- and Dose-Dependent Downregulation of Tyrosine Hydroxylase in the Intact Nigrostriatal Dopamine System. Journal of Neuroscience, 2004, 24, 6437-6445.	3.6	140
28	Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders. Current Gene Therapy, 2008, 8, 461-473.	2.0	139
29	Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of <scp>l</scp> -dopa using rAAV-mediated gene transfer. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4708-4713.	7.1	137
30	In Vivo Protection of Nigral Dopamine Neurons by Lentiviral Gene Transfer of the Novel GDNF-Family Member Neublastin/Artemin. Molecular and Cellular Neurosciences, 2000, 15, 199-214.	2.2	134
31	The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinsonâ€™s disease. Brain, 2010, 133, 482-495.	7.6	125
32	Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. NeuroReport, 2002, 13, 75-82.	1.2	123
33	Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. European Journal of Neuroscience, 2009, 30, 625-638.	2.6	116
34	Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. European Journal of Neuroscience, 2001, 13, 1589-1599.	2.6	115
35	Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. European Journal of Neuroscience, 2003, 17, 260-270.	2.6	114
36	How is alphaâ€synuclein cleared from the cell?. Journal of Neurochemistry, 2019, 150, 577-590.	3.9	113

#	Article	IF	Citations
37	Serotoninâ€“dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Progress in Brain Research, 2008, 172, 465-478.	1.4	110
38	Proton NMR of ¹⁵N-Choline Metabolites Enhanced by Dynamic Nuclear Polarization. Journal of the American Chemical Society, 2009, 131, 16014-16015.	13.7	107
39	Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiology of Disease, 2006, 21, 657-668.	4.4	105
40	Global Optogenetic Activation of Inhibitory Interneurons during Epileptiform Activity. Journal of Neuroscience, 2014, 34, 3364-3377.	3.6	103
41	Growth and Functional Efficacy of Intrastriatal Nigral Transplants Depend on the Extent of Nigrostriatal Degeneration. Journal of Neuroscience, 2001, 21, 2889-2896.	3.6	100
42	Viral vector-mediated overexpression of Î±-synuclein as a progressive model of Parkinsonâ€™s disease. Progress in Brain Research, 2010, 184, 89-111.	1.4	99
43	Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends in Neurosciences, 2003, 26, 386-392.	8.6	96
44	Regulated Delivery of Glial Cell Line-Derived Neurotrophic Factor into Rat Striatum, Using a Tetracycline-Dependent Lentiviral Vector. Human Gene Therapy, 2004, 15, 934-944.	2.7	96
45	Feasibility of in vivo15N MRS detection of hyperpolarized 15N labeled choline in rats. Physical Chemistry Chemical Physics, 2010, 12, 5818.	2.8	96
46	Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Experimental Neurology, 2003, 184, 536-548.	4.1	94
47	Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathologica, 2010, 120, 777-788.	7.7	93
48	Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain, 2008, 132, 319-335.	7.6	90
49	Coâ€expression of Câ€terminal truncated alphaâ€synuclein enhances fullâ€length alphaâ€synucleinâ€induced pathology. European Journal of Neuroscience, 2010, 32, 409-422.	2.6	90
50	Mutant Huntingtin Causes Metabolic Imbalance by Disruption of Hypothalamic Neurocircuits. Cell Metabolism, 2011, 13, 428-439.	16.2	90
51	Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiology of Disease, 2006, 23, 522-532.	4.4	89
52	Seizure Suppression by GDNF Gene Therapy in Animal Models of Epilepsy. Molecular Therapy, 2007, 15, 1106-1113.	8.2	87
53	Chapter 11 Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement. Progress in Brain Research, 2000, 127, 233-265.	1.4	85
54	How can <scp>rAAV</scp>â€Î±â€synuclein and the fibril Î±â€synuclein models advance our understanding of Parkinson's disease?. Journal of Neurochemistry, 2016, 139, 131-155.	3.9	84

#	Article	IF	Citations
55	Differential Transduction Following Basal Ganglia Administration of Distinct Pseudotyped AAV Capsid Serotypes in Nonhuman Primates. Molecular Therapy, 2010, 18, 579-587.	8.2	82
56	GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. Journal of Comparative Neurology, 2012, 520, 2591-2607.	1.6	76
57	Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain, 2005, 128, 559-569.	7.6	74
58	Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiology of Disease, 2010, 40, 531-543.	4.4	74
59	Dose Optimization for Long-term rAAV-mediated RNA Interference in the Nigrostriatal Projection Neurons. Molecular Therapy, 2009, 17, 1574-1584.	8.2	67
60	Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease. Human Molecular Genetics, 2013, 22, 3485-3497.	2.9	67
61	Functional Convergence of Dopaminergic and Cholinergic Input Is Critical for Hippocampus-Dependent Working Memory. Journal of Neuroscience, 2008, 28, 7797-7807.	3.6	62
62	Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats. Neurobiology of Disease, 2003, 14, 542-556.	4.4	58
63	Anterograde delivery of brainâ€derived neurotrophic factor to striatum via nigral transduction of recombinant adenoâ€associated virus increases neuronal death but promotes neurogenic response following stroke. European Journal of Neuroscience, 2003, 17, 2667-2678.	2.6	56
64	Viral Delivery of GDNF Promotes Functional Integration of Human Stem Cell Grafts in Parkinsonâ€™s Disease. Cell Stem Cell, 2020, 26, 511-526.e5.	11.1	56
65	Isolation and characterization of neural precursor cells from theSox1-GFP reporter mouse. European Journal of Neuroscience, 2005, 22, 1555-1569.	2.6	53
66	Dysregulated dopamine storage increases the vulnerability to Î±-synuclein in nigral neurons. Neurobiology of Disease, 2012, 47, 367-377.	4.4	53
67	Presynaptic dopaminergic compartment determines the susceptibility to L-DOPAâ€“induced dyskinesia in rats. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13159-13164.	7.1	48
68	Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Experimental Neurology, 2005, 193, 65-74.	4.1	45
69	Restoration of the Striatal Dopamine Synthesis for Parkinsons Disease:Viral Vector-Mediated Enzyme Replacement Strategy. Current Gene Therapy, 2007, 7, 109-120.	2.0	45
70	Organotypic slice culture model demonstrates inter-neuronal spreading of alpha-synuclein aggregates. Acta Neuropathologica Communications, 2019, 7, 213.	5.2	45
71	Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. Neurobiology of Aging, 2013, 34, 873-886.	3.1	44
72	Optogenetic inhibition of chemically induced hypersynchronized bursting in mice. Neurobiology of Disease, 2014, 65, 133-141.	4.4	44

#	Article	IF	Citations
73	Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinsonâ€™s disease. Brain, 2010, 133, 496-511.	7.6	42
74	Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Neurobiology of Disease, 2013, 56, 47-58.	4.4	42
75	LAMP2A as a therapeutic target in Parkinson disease. Autophagy, 2013, 9, 2166-2168.	9.1	41
76	Neurturin enhances the survival of intrastriatal fetal dopaminergic transplants. NeuroReport, 1999, 10, 1783-1887.	1.2	40
77	Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiology of Disease, 2017, 97, 179-188.	4.4	40
78	A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Molecular Neurodegeneration, 2016, 11, 61.	10.8	39
79	Functional properties and synaptic integration of genetically labelled dopaminergic neurons in intrastriatal grafts. European Journal of Neuroscience, 2005, 21, 2793-2799.	2.6	35
80	Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system. Human Molecular Genetics, 2012, 21, 874-889.	2.9	34
81	The Functional Impact of the Intrastriatal Dopamine Neuron Grafts in Parkinsonian Rats Is Reduced with Advancing Disease. Journal of Neuroscience, 2007, 27, 5849-5856.	3.6	33
82	Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathologica Communications, 2017, 5, 47.	5.2	33
83	Positron Emission Tomography Imaging Demonstrates Correlation between Behavioral Recovery and Correction of Dopamine Neurotransmission after Gene Therapy. Journal of Neuroscience, 2009, 29, 1544-1553.	3.6	32
84	Viral Vector Mediated Overexpression of Human Î±-Synuclein in the Nigrostriatal Dopaminergic Neurons: A New Model for Parkinson's Disease. CNS Spectrums, 2005, 10, 235-244.	1.2	31
85	Selective loss of oxytocin and vasopressin in the hypothalamus in early <scp>H</scp>untington disease: a case study. Neuropathology and Applied Neurobiology, 2015, 41, 843-848.	3.2	31
86	Volumetric Analysis of the Hypothalamus in Huntington Disease Using 3T MRI: The IMAGE-HD Study. PLoS ONE, 2015, 10, e0117593.	2.5	30
87	Gene Therapy for Dopamine Replacement in ParkinsonÂ´s Disease. Science Translational Medicine, 2009, 1, 2ps2.	12.4	29
88	Design of a Single AAV Vector for Coexpression of TH and GCH1 to Establish Continuous DOPA Synthesis in a Rat Model of Parkinson's Disease. Molecular Therapy, 2012, 20, 1315-1326.	8.2	27
89	The behavioural and neuropathological impact of intranigral AAV-Î±-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats. Behavioural Brain Research, 2013, 243, 6-15.	2.2	26
90	Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor. European Journal of Neuroscience, 2004, 20, 3121-3130.	2.6	25

#	Article	IF	Citations
91	Huntingtonâ€™s Disease â€“ New Perspectives Based on Neuroendocrine Changes in Rodent Models. Neurodegenerative Diseases, 2009, 6, 154-164.	1.4	25
92	Ser129 phosphorylation of endogenous Î±-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function. Neurobiology of Disease, 2015, 78, 100-114.	4.4	24
93	Adeno-associated viral vector serotypes 1 and 5 targeted to the neonatal rat and pig striatum induce widespread transgene expression in the forebrain. Experimental Neurology, 2010, 222, 70-85.	4.1	23
94	Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease. Movement Disorders, 2021, 36, 2085-2093.	3.9	23
95	A combined cell and gene therapy approach for homotopic reconstruction of midbrain dopamine pathways using human pluripotent stem cells. Cell Stem Cell, 2022, 29, 434-448.e5.	11.1	23
96	Characterization of Cognitive Deficits in Rats Overexpressing Human Alpha-Synuclein in the Ventral Tegmental Area and Medial Septum Using Recombinant Adeno-Associated Viral Vectors. PLoS ONE, 2013, 8, e64844.	2.5	21
97	Toxic effects of human and rodent variants of alphaâ€synuclein <i>inÂvivo</i>. European Journal of Neuroscience, 2017, 45, 536-547.	2.6	21
98	An investigation of the problem of two-layered immunohistochemical staining in paraformaldehyde fixed sections. Journal of Neuroscience Methods, 2006, 158, 64-74.	2.5	20
99	Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Movement Disorders, 2013, 28, 1351-1359.	3.9	20
100	Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Scientific Reports, 2013, 3, 2157.	3.3	19
101	Interaction between subclinical doses of the Parkinsonâ€™s disease associated gene, Î± -synuclein , and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats. Behavioural Brain Research, 2017, 316, 160-168.	2.2	19
102	Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease. Molecular Therapy, 2015, 23, 896-906.	8.2	18
103	Imaging in cell-based therapy for neurodegenerative diseases. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, S417-S434.	6.4	16
104	Differential Dopamine Receptor Occupancy Underlies L-DOPA-Induced Dyskinesia in a Rat Model of Parkinson's Disease. PLoS ONE, 2014, 9, e90759.	2.5	16
105	Altered profile of basket cell afferent synapses in hyperâ€excitable dentate gyrus revealed by optogenetic and twoâ€pathway stimulations. European Journal of Neuroscience, 2012, 36, 1971-1983.	2.6	15
106	In vivo quantification of glial activation in minipigs overexpressing human Î±â€synuclein. Synapse, 2018, 72, e22060.	1.2	15
107	Enhanced Dopamine in Prodromal Schizophrenia (EDiPS): a new animal model of relevance to schizophrenia. NPJ Schizophrenia, 2019, 5, 6.	3.6	15
108	Optimization of continuous <i>in vivo</i> DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats. Journal of Neurochemistry, 2009, 111, 355-367.	3.9	14

#	Article	IF	Citations
109	Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiology of Disease, 2021, 148, 105184.	4.4	14
110	DNAJB6 suppresses alpha-synuclein induced pathology in an animal model of Parkinson's disease. Neurobiology of Disease, 2021, 158, 105477.	4.4	14
111	Brain area, age and viral vector-specific glial cell-line-derived neurotrophic factor expression and transport in rat. NeuroReport, 2007, 18, 845-850.	1.2	12
112	Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs. Scientific Reports, 2018, 8, 15715.	3.3	12
113	Characterization of a rat model of Huntingtonâ€™s disease based on targeted expression of mutant <i>huntingtin</i> in the forebrain using adenoâ€associated viral vectors. European Journal of Neuroscience, 2012, 36, 2789-2800.	2.6	11
114	Targetedin uterodelivery of a retroviral vector for gene transfer in the rodent brain. European Journal of Neuroscience, 2006, 24, 1897-1906.	2.6	10
115	Quantification of Total and Mutant Huntingtin Protein Levels in Biospecimens Using a Novel alphaLISA Assay. ENeuro, 2018, 5, ENEURO.0234-18.2018.	1.9	10
116	Histological analysis of fetal dopamine cell suspension grafts in two patients with Parkinson's disease gives promising results. Brain, 2005, 128, 1478-1479.	7.6	9
117	Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain. Neurobiology of Disease, 2012, 48, 222-227.	4.4	8
118	Development of <scp>NMR</scp> spectroscopic methods for dynamic detection of acetylcholine synthesis by choline acetyltransferase in hippocampal tissue. Journal of Neurochemistry, 2013, 124, 336-346.	3.9	8
119	Preserved Function of Afferent Parvalbumin-Positive Perisomatic Inhibitory Synapses of Dentate Granule Cells in Rapidly Kindled Mice. Frontiers in Cellular Neuroscience, 2017, 11, 433.	3.7	8
120	Two C-terminal sequence variations determine differential neurotoxicity between human and mouse Î±-synuclein. Molecular Neurodegeneration, 2020, 15, 49.	10.8	6
121	Positive symptom phenotypes appear progressively in â€œEDiPSâ€, a new animal model of the schizophrenia prodrome. Scientific Reports, 2021, 11, 4294.	3.3	6
122	Acute Contractile Effects of Epidermal Growth Factor on Bladder Smooth Muscles: An <i>In Vivo</i> and <i>In Vitro</i> Study in Rats. Scandinavian Journal of Urology and Nephrology, 1997, 31, 231-235.	1.4	5
123	In vivo gene delivery to proliferating cells in the striatum generated in response to a 6-hydroxydopamine lesion of the nigro-striatal dopamine pathway. Neurobiology of Disease, 2008, 30, 343-352.	4.4	5
124	Overexpression of Î±-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity. BMC Neuroscience, 2015, 16, 86.	1.9	5
125	Development of advanced therapies based on viral vector-mediated overexpression of therapeutic molecules and knockdown of disease-related genes for Parkinsonâ€™s disease. Therapeutic Delivery, 2011, 2, 37-50.	2.2	4
126	Introduction. Neurobiology of Disease, 2012, 48, 151-152.	4.4	3

#	Article	IF	Citations
127	Assessment of brain metabolite correlates of adenoâ€associated virusâ€mediated overâ€expression of human alphaâ€synuclein in cortical neurons by <i>inÂvivo</i>¹Hâ€<scp>MR</scp> spectroscopy at 9.4 T. Journal of Neurochemistry, 2016, 137, 806-819.	3.9	3
128	Effects of mutant huntingtin inactivation on Huntington diseaseâ€related behaviours in the BACHD mouse model. Neuropathology and Applied Neurobiology, 2021, 47, 564-578.	3.2	1
129	Twisting mice move the dystonia field forward. Journal of Clinical Investigation, 2014, 124, 2848-2850.	8.2	1
130	Future Cell- and Gene-Based Therapies for Parkinson's Disease. , 2008, , 145-156.		0
131	A44â€…Analysis of the deletion of mutant huntingtin from A2A-receptor expressing neurons. , 2018, , .		0
132	Adult Bone Marrow-Derived Cell Fusion with Cardiomyocytes and Purkinje Neurons in Response to Irradiation but Not in Steady State.. Blood, 2004, 104, 3604-3604.	1.4	0